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Introduction
Hemodynamic measures such as right atrial pressure (RAP), mean pulmonary artery pressure (mPAP), and cardiac index (CI) are the cornerstones of diagnosis and risk assessment in pulmonary arterial hypertension (PAH). [1] [2] [3] As such, hemodynamics often serve as primary or secondary endpoints in Phase II trials of investigational PAH therapies as a signal for efficacy. [4] [5] [6] [7] [8] While the United States Food and Drug Administration (FDA) does not consider hemodynamics as adequate surrogate or primary endpoints, many Phase III trials of currently approved PAH treatments have included hemodynamics as secondary endpoints. [9] [10] [11] [12] [13] [14] [15] [16] Given the absence of other well-established surrogate endpoints in PAH, the validation of hemodynamic markers as surrogate endpoints in PAH would be critical to improving the efficiency of drug evaluation.
Contrary to conventional wisdom, a recent study-level meta-analysis suggested that changes in hemodynamic measures with PAH therapy might not predict clinical events. 17 The objective of our study was to determine whether changes in RAP, mPAP, cardiac output (CO), CI, and pulmonary vascular resistance (PVR) are valid surrogate endpoints in PAH clinical trials using a mediator analytic approach with patient-level data, the "gold standard" approach to synthesizing data across trials. 18, 19 We pooled individual-level data from four randomized placebo-controlled trials submitted to the FDA for drug approval. We hypothesized that changes in hemodynamics at 12 weeks (adjusted for measures at baseline) would account for a significant portion of the relationship between treatment assignment and the odds of a clinical event,
validating hemodynamics as surrogate endpoints in PAH.
Methods

Study Population
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Details of these trials are provided elsewhere, but all had similar inclusion criteria and data collection processes. [10] [11] [12] [13] [14] [15] [20] [21] [22] [23] We included patients from Phase III trials which collected baseline and 12-week hemodynamic values. We excluded patients with missing baseline hemodynamics and one study (PHIRST) because some subjects in this trial had been treated with background bosentan therapy. 24 ARIES 1&2, BREATHE-1, STRIDE-2 and -4 were excluded because these trials did not assess hemodynamics at 12 weeks; Bosentan-351 and AIR II were excluded because they were small or not Phase III trials. The final study population included patients from four trials (AIR, SUPER, STRIDE-1, and subcutaneous treprostinil) of four therapies (iloprost, sildenafil, sitaxsentan, and subcutaneous treprostinil, respectively).
Clinical Events
Clinical events included the first occurrence of any of the following prior to the end of the randomized portion of the trials: death, lung transplantation, atrial septostomy, hospitalization due to worsening PAH, withdrawal for clinical worsening, or escalation in PAH therapy. We did not include change in six-minute walk distance (6MWD) as a clinical event in the primary analysis, because it has not been established as a patient-centered outcome and is itself an imperfect surrogate for clinical outcomes in PAH. 25, 26 Sensitivity analyses including a decrement in 6MWD in the composite endpoint were performed (described below).
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Hemodynamics
Hemodynamic values at baseline and at 12 weeks as reported to the FDA were used to calculate the absolute change in RAP ( RAP), mPAP ( mPAP), CO ( CO), CI ( CI), and PVR ( PVR).
In addition to traditional hemodynamic measures, we included pulmonary artery (PA) compliance, calculated as follows: (CO/heart rate)/(systolic PAP -diastolic PAP). 
Statistical Analysis
Continuous variables were expressed as median (interquartile range) and categorical variables were expressed as percentages. We employed a mediator analysis which is the preferred approach to validating potential surrogate endpoints. 30, 31 Treatment assignment was designated as either active treatment or placebo. Regression analysis was used to evaluate four hypotheses.
The rejection of all four null hypotheses was required to deem the change in a given hemodynamic measure a valid surrogate endpoint. The four alternative hypotheses included:
1. Treatment assignment has a significant effect on change in hemodynamics ( RAP, mPAP, CO, CI, PVR and PA compliance) at 12-weeks;
2.
Change in hemodynamics ( RAP, mPAP, CO, CI, PVR and PA compliance) has a significant association with the odds of a clinical event;
3. Treatment assignment has a significant effect on the odds of a clinical event;
4.
The effect of treatment assignment on the odds of a clinical event is attenuated when change in a given hemodynamic parameter ( RAP, mPAP, CO, CI, PVR and PA compliance) is added to the model. Logistic or linear regression was used for binary or continuous outcomes, respectively. All were expressed as percentages. We employed a mediator analysis which is the p pr re refe fe err red ed ed approach to validating potential surrogate endpoints. 30, 31 Treatment assignment was designated as s e e eit it ithe he her ac ac cti ti tiv v ve t tre re rea at atment or placebo. Regression n an an nalysis was use e ed d to o e e ev va valuate four hypotheses.
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Following the tests for mediation, we determined the proportion of the treatment effect (PTE) explained by RAP, mPAP, CO, CI, PVR and PA compliance, respectively. 32, 33 Generalized linear modeling with a logit link was used to determine the effect estimate for treatment assignment and log odds of a clinical event, adjusted for baseline hemodynamic value and study. RAP, mPAP, CO, CI, PVR and PA compliance were then individually added to the initial models, such that the change in the effect estimates between baseline and those containing the hemodynamic mediator provided the amount of variability in clinical events explained by a change in the mediator at 12 weeks. Estimates of percent change were obtained for each resampled dataset, and the standard deviation of the estimates across 1000 resampled datasets were used as the standard error. 34 A number of sensitivity and subset analyses were performed. First, the clinical event definition was expanded to include a 15% decrement in 6MWD during the randomized portion of the trials (in addition to death, lung transplantation, atrial septostomy, hospitalization due to worsening PAH, withdrawal for clinical worsening, or escalation in PAH therapy). Those missing 12-week 6MWD values were counted as having had an event. Second, we tested whether achieving certain established thresholds of hemodynamic improvement (i.e., CI > 2 L/min/m 2 or > 3 L/min/m 2 , reduction in PVR > 30% at 12 weeks), using absolute values of hemodynamics (rather than the change values), and nonparametric modeling (using local smoothers) revealed alternative hemodynamic cutpoints which performed better as surrogates. 1, 3, 35 Third, we adjusted our primary analysis for New York Heart Association (NYHA) functional class. Fourth, we included subset analyses limiting our study population to those with idiopathic PAH, connective tissue disease (CTD) and congenital heart disease associated PAH, respectively, for each resampled dataset, and the standard deviation of the estimates across 10 00 00 0 res es sam am ampl pl pled ed e datasets were used as the standard error.
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Results
The final study sample included 1119 patients from four trials (AIR, SUPER, STRIDE-1, and Characteristics of the study population and those receiving active treatment (N = 656, 59%) or placebo (N = 463, 41%) are shown in Table 1 . The median age was 48 (range 37 -59) years and predictors in the imputation models for the missing 12-week hemodynamic valu ue e es. Al Al All l an an anal al alys ys y es e were performed using SAS version 9.2 and R, version 2.14. esponsibility ty y f f for or o t t the he he a a ana na n ly y ysi si s s, s s a a and nd nd h h hav ave e e co co cont nt n ri ri ribu bu b t t ted ed ed t t to o ma ma manu nu nusc sc cri ri ript p p p p pre re repa pa para ra rati ti tion on n a a and nd nd t t the he h decision t to o 23% were men. Six hundred and thirty seven patients (60%) had idiopathic PAH, 247 (23%) had Table 2 ). Second, the relationship between the change in a given hemodynamic value at 12 weeks and the odds of a clinical event was tested (Criterion #2; Table 3 Table 4 ).
Fourth, we assessed the change in the treatment ORs for clinical events after adjustment for the change in a given hemodynamic value at 12 weeks (Criterion #4; Table 4 ). There were no presented in Tables 2-4 . Assignment to active treatment significantly reduced RA RA AP, P, P, m m mPA PA PAP, P, P, a an nd PVR and increased CO, CI, and PA compliance (Criterion #1; Table 2 ). Second, the relationship be etw tw wee ee een n th th the e e c c chan an ng ge ge in a given hemodynamic va a alu lu lue e at 12 weeks an an nd th h he e e o o odds of a clinical event w was s s te t sted (Cr rit ite e eri io on n #2 #2 # ; ; ; Ta Ta Tabl bl ble e 3 3). ). ). D D De ec cr rease e e i in n PVR VR V a and nd nd i in n ncr re reas as ses s s in in C C CO O O an an nd d d CI CI w w wer er e e e as s sso soc ci c a a ated wi wi ith th th s s sig ig igni nifi fi fica ca cant nt r r red d duc uct tio on ons s in n n the he he od od odds ds o of f f a a a c c clin in nic ica a al e eve ve ent nt nt. . E E Effe fe fect ct e est st stim im i a a ate es es a a app pp ppea ea e r r r sm sm smal al ll a as as t th he hey y y efer to the o odd dd dds s s of of of a a a c c cli li ini n ca ca cal l l ev ev ven en ent t pe pe p r r 1 1 1 un un unit it i i i inc nc n re re reas as se e in in n t the he he h h hem em emod d dyn yn ynam am amic ic ic m mea ea easu su sure re re ( ( (e. e g., odds was not met for any hemodynamic measure. Therefore, rejection of the null hypotheses was not possible, suggesting that no hemodynamic measure appeared to be a valid surrogate.
We next quantified the proportion of the treatment effect (PTE) explained by the hemodynamic change values (Figure 1 ). These mediators accounted for little ( CO, CI, PVR)
to none ( RAP, mPAP, PA compliance) of the treatment effect. At most, CI and PVR accounted for 11.7% and 13.9% of the impact of treatment on clinical outcomes, well-below the proposed cutoff of 50-75% necessary to declare a surrogate valid.
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Sensitivity and Subset Analyses
The results were unchanged when a 15% decrement in 6MWD was included in the definition of a clinical event ( Table 5 ). The ORs shown for Criterion #4 were not substantially attenuated with inclusion of the hemodynamic measures compared to the models for Criterion #3. While the PTEs were generally greater than in the main analysis (e.g., PVR accounted for 26.9% of the treatment-clinical event relationship), they were still well below 50%, suggesting the hemodynamic change values were not acting as mediators. Similarly, analyses using predefined 
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Th The e re re esu su sult lt lts s s we ere re re u u unc nc ncha ha hang ng nged e w whe he hen n n a a 15 5% % % d de decr cr crem em men en ent t t in in 6 6 6MW MW MWD D D wa wa was s s in in ncl cl clud ud uded ed i i in n n th th the e de de efi fi fini ni niti ti tion on on o o of f a clinical eve vent nt t ( ( (Ta Ta T bl b ble e 5 5 5). ). T T The he h O ORs Rs R s sho hown wn f for or C C Cri rite teri i rion on # # #4 4 we were re n not ot t s s b ub ubst stan anti tial ally ly a att tten enuated our primary analysis (Supplemental Table 1 ). In the small subgroups of patients with CTD, congenital heart disease, and those patients who achieved a 6MWD > 380 m at 12 weeks (N = 469), findings were also unchanged although the estimates were imprecise due to a very low number of events (N = 21, 11, and 9 events, respectively) (data not shown). We repeated our analysis substituting hemodynamic values 60 minutes post-iloprost inhalation (in patients from the AIR study) in order to calculate the change values and the results were nearly identical (Supplemental Table 2 ).
Discussion
Based on this large pooled analysis of patient-level data we are unable to conclude that treatment and the restriction of the study sample to patients with idiopathic PAH.
The use of hemodynamic measures as surrogate endpoints in PAH clinical trials is appealing, given that these measures may in theory be standardized, are widely available, and are integral to our understanding and definition of PAH. 38, 39 Observational studies have consistently shown associations between hemodynamics (especially those that pertain to right heart function, such as CO) and event-free survival (as seen in this study); however, such observational data are Based on this large pooled analysis of patient-level data we are unable to conclu ud de de t t tha ha at t tr r trea ea eatm tm tmen e t nduced changes in resting hemodynamics are valid surrogate endpoints for short-term outcomes n n P P PAH AH AH. Wh Wh Whil ile 1) 1) ) a a act c ive treatment was significan an ant tly y y associated w wit it i h mo mo od de dest improvement in h he hem mo modynamics cs a a at 12 12 w w we ee eeks ks ks, , 2) 2) 2) c cha ha han ng nge e es in s so om m me h h he em mod od dy yn ynam am mic ics s w were re s s sig g gni nifi fi fic ca cant ntly ly ly a a ass ssoc oc ocia ia iate te ed wi wi ith th th t t the he h o odd dd dds s s of of cl li lini nic c cal l l e eve vent nt n s, s a a and nd nd 3 3) ) ) tr tr rea ea eat tm tmen en ent t as as ssi s g gn gnme me men nt nt co co c n ns nsid id ider er e a a ably ly ly r r red ed educ uc u ed ed ed t t the he e o odd dd d s s of f f a a clinical event nt, , th th he e re re rela la ati ti t on o o sh sh ship ip ip b b bet et etwe we ween en n t tre re reat at atm m men en e t t t an an and d d cl cl lin in inic ic ical a a e e eve ve v nt nt ts s s wa wa was s s no no not t me me medi di d at at ated ed e or not sufficient to validate potential surrogates. Although we incorporated a measure of PA compliance in our study, there may be more sophisticated and comprehensive measures of the cardiopulmonary interaction which prove to be valid surrogates in PAH.
While short-term hemodynamic response may be a poor surrogate for short-term clinical events, these results may not apply to trials of longer duration. It is possible that changes in hemodynamics following longer-term therapy are adequate surrogates for long-term outcomes.
We are not able to answer this question, since essentially all clinical trials including cardiac MRI in a large-scale fashion in PAH clinical trials, other RV biomarkers s ma ma ay pr pr prov ov ove e e to to be better surrogates. Advanced or novel RV imaging techniques, such as speckle-tracking Doppler an nd d d po po posi si sitr tr tron on on e emi mi iss ss ssio ion tomography, have been li in nk nke e ed to clinical d det e e erio io ora ra rati t on and RV metabolic d h ch han n anges in PAH AH, , r re esp spec ecti ti tive ve ely ly y, , al alth th ho ou oug gh h m mor r re wor rk rk is ne ne need eded ed ed t to o es s sta tabl bl blis i i h h h cl cl lea ea ear r co co orr rr r el el elat at tio o on ns ns k be etw tw twee ee een n th th hes es ese e m m mea as asur ur res es, , , PA PAH H H tr tr trea ea eatm tm tme en nt t t re re res sp spon on onse se e, a an a d d d ou ou outc tc tcom m mes es s. All models include adjustment for baseline hemodynamic value and study. OR=odds ratio; CI=confidence interval; RAP=change in right atrial pressure; mPAP=change in mean pulmonary artery pressure; CO=change in cardiac output; CI=change in cardiac index; PVR=change in pulmonary vascular resistance; PA compliance=change in pulmonary artery compliance. odels include adjustment for the listed baseline hemodynamic value and study. OR=odds ratio; CI=confidence interval; RAP=right atrial pressure; =mea ean n pu pu pulm lm lmon on onar ar a y y y ar ar a tery y ry pre e r ss s ure; CO=cardiac output; CI=cardiac index; ; ; PV PV PVR= R R pulmonary vascular resis a tanc nc n e; e; PA=pulmonary artery. r r Table 5 . Criteria to establish the change in a hemodynamic measure ( HD) as a mediator in the relationship between treatment assignment and clinical events including a 15% decrement in 6MWD at 12 weeks. 
